ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models

•ER2 suppressed EGFR pathway and induced G1 arrest and apoptosis in NSCLC cells.•ER2 inhibited EGF-stimulated VEGF production.•ER2 induced anti-tumor activity in combination with cisplatin in xenograft models. The epidermal growth factor receptor (EGFR) abnormalities including amplification, mutatio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-05, Vol.95, p.57-64
Hauptverfasser:	Kang, Han Na, Kim, Se-Ho, Yun, Mi Ran, Kim, Hye Ryun, Lim, Sun Min, Kim, Min-Soo, Hong, Kwang-Won, Kim, Sung-Moo, Kim, Hwan, Pyo, Kyoung-Ho, Park, Hye Ji, Han, Joo Yeun, Youn, Hyun A, Chang, Ki-Hwan, Cho, Byoung Chul
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal, Humanized - pharmacology Antineoplastic Agents - pharmacology Apoptosis - drug effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Cycle Checkpoints - drug effects Cell Line, Tumor Cetuximab Cisplatin - pharmacology Disease Models, Animal Drug Synergism Epidermal growth factor receptor ER2 Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Mice Monoclonal antibody Non-small cell lung cancer Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Signal Transduction - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!